ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Memory of the renin-angiotensin system following heart transplantation or implantation of a left ventricular assist device.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundRenin-angiotensin system (RAS) inhibitors, while not routinely recommended after heart transplantation (HT), are advised in left ventricular assist device (LVAD) recipients to promote reverse remodeling and support myocardial recovery. Whether restoring hemodynamics through HT or LVAD implantation sufficiently resolves neurohormonal activation remains uncertain.
methodsPatients with end-stage heart failure undergoing HT or LVAD implantation were enrolled in a prospective registry. NT-proBNP, plasma active renin concentration (ARC), aldosterone levels, and the complete profile of angiotensin metabolites were assessed before and after the intervention in 49 HT and 12 LVAD recipients.
resultsThe use of RAS inhibitors was significantly reduced after HT (p < 0.001) and remained comparable in LVAD patients (p = 0.453). Both HT and LVAD were associated with reductions in NTproBNP (3015 to 1140 pg/mL; p < 0.001; 8980 to 1836 pg/mL; p = 0.002) and ARC levels (278 to 87µIU/mL; p < 0.001; 847 to 131 µIU/mL; p = 0.074), which was accompanied by a decrease in the angiotensin burden of the classical RAS axis (AngI + AngII: 159 to 47 ng/L, p < 0.001; 214 to 42 ng/L, p = 0.155). However, no patient showed normalization of NT-proBNP levels. Additionally, plasma renin remained elevated in 76% of HT and 67% of LVAD recipients, accompanied by detectable Ang II levels.
conclusionContinuing AngII spill-over after HT and LVAD may affect patient outcomes, potentially contributing to complications. The findings support the rationale for cardioprotective treatment, particularly with RAS inhibitors, in most patients, while further studies should address the long-term effect of this strategy.
Indexed as
Identifiers
42771189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.